| 1 |
A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk
Troy M. Bremer, Pat W. Whitworth, Rakesh P. Patel et al. · Clinical Cancer Research
|
27 Jul 2018 |
128 |
| 2 |
The Clinical Utility of DCISionRT® on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery
Chirag Shah et al. · Annals of Surgical Oncology
Open access |
5 Apr 2021 |
58 |
| 3 |
Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS)
Fredrik Wärnberg, Per Karlsson, Erik C. Holmberg et al. · Cancers
Open access |
3 Dec 2021 |
55 |
| 4 |
A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy
Frank A. Vicini, G. Bruce Mann, Chirag Shah et al. · International Journal of Radiation Oncology*Biology*Physics
Open access |
15 Sep 2022 |
36 |
| 5 |
Quantitative comparison of immunohistochemical HER2 ‐low detection in an interlaboratory study
Maaike Anna Hempenius, Maran A Eenkhoorn, Henrik Høeg et al. · Histopathology
Open access |
29 Jul 2024 |
28 |
| 6 |
A Consortium for Analytic Standardization in Immunohistochemistry
Steven A. Bogen, David J. Dabbs, Keith D. Miller et al. · Archives of Pathology & Laboratory Medicine
Open access |
May 2022 |
25 |
| 7 |
Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial
Aglaia Schiza, Viktoria Thurfjell, Axel Stenmark Tullberg et al. · European Journal of Cancer
Open access |
27 Feb 2022 |
24 |
| 8 |
The Clinical Utility of a 7-Gene Biosignature on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery: An Updated Analysis of the DCISionRT® PREDICT Study
Chirag Shah et al. · Annals of Surgical Oncology
Open access |
25 Jun 2024 |
21 |
| 9 |
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4 -Mutated Cancers
Michael W Hulse et al. · Cancer Research
|
24 Sep 2025 |
20 |
| 10 |
High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial
Carina Strell, Dick Folkvaljon, Erik C. Holmberg et al. · Clinical Cancer Research
Open access |
5 May 2021 |
16 |
| 11 |
Avoiding “False Positive” and “False Negative” Immunohistochemical Results in Breast Pathology
Zaibo Li, David J. Dabbs · Pathobiology
Open access |
2022 |
14 |
| 12 |
The Story of the Magee Equations: The Ultimate in Applied Immunohistochemistry
Rohit Bhargava, David J. Dabbs · Applied immunohistochemistry & molecular morphology
Open access |
21 Sep 2022 |
12 |
| 13 |
Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ
David J. Dabbs, Karuna Mittal, SCOTT HEINEMAN et al. · Frontiers in Oncology
Open access |
19 May 2023 |
11 |
| 14 |
Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk Ductal Carcinoma In Situ After Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Recurrence Rates
Frank A. Vicini et al. · International Journal of Radiation Oncology*Biology*Physics
Open access |
18 Jul 2025 |
5 |
| 15 |
Lack of Standardization in the Diagnosis of Invasive Lobular Carcinoma of the Breast
Benjamin C. Calhoun, David J. Dabbs · Modern Pathology
Open access |
2023 |
5 |
| 16 |
In Support of Magnani and Taylor
David J. Dabbs, Luis A. Chiriboga, Bharat Jasani et al. · Archives of Pathology & Laboratory Medicine
Open access |
29 Dec 2023 |
4 |
| 17 |
A 7-Gene Biosignature for Ductal Carcinoma in situ of the Breast Identifies Subpopulations of HER2-positive Patients With Distinct Recurrence Rates After Breast-Conserving Surgery and Radiation Therapy
Frank A. Vicini, Chirag S. Shah, Karuna Mittal et al. · Clinical Breast Cancer
Open access |
4 Sep 2024 |
2 |
| 18 |
Novel markers in breast pathology
David J. Dabbs, Richard S.P. Huang, Jeffrey S. Ross · Histopathology
|
5 Dec 2022 |
2 |
| 19 |
Re-Thinking Clinicopathologic Risk Assessment in DCIS: Pooled Data from Validation Studies Comparing a 7-gene DCIS Assay to Clinicopathologic Features Alone
Chintan Shah, F.A. Vicini, F. Wärnberg et al. · International Journal of Radiation Oncology*Biology*Physics
|
22 Oct 2022 |
2 |
| 20 |
CLO25-061: 7-Gene Biosignature Reclassified Women With DCIS Meeting NCCN Guideline (RTOG 9804-Like) Low-Risk Criteria as Molecular High Risk
Chirag S. Shah, Frank A. Vicini, Eileen P. Connolly et al. · Journal of the National Comprehensive Cancer Network
|
28 Mar 2025 |
1 |
| 21 |
Biosignatures to Optimize Adjuvant Radiation Therapy Use in Patients With DCIS With High Risk Clinicopathologic Features
Frank A. Vicini, Chirag Shah, Pat W. Whitworth et al. · International Journal of Radiation Oncology*Biology*Physics
Open access |
25 Oct 2021 |
1 |
| 22 |
The challenge of plurality. A comment on the occasion of the journal L1-Educational Studies in Language and Literature being 20
Irene Pieper · L1 Educational Studies in Language and Literature
Open access |
Aug 2021 |
1 |
| 23 |
Periductal myxoid stroma identifies ductal carcinoma in situ at risk of invasive recurrence
Aglaia Schiza, Viktoria Thurfjell, Erik Holmberg et al. · JNCI Journal of the National Cancer Institute
Open access |
21 Aug 2026 |
0 |
| 24 |
Beyond Fluent Replies: Evaluating Prelude as a Conversation Decision System for Emotionally Loaded Romantic Conversations
Mariia Yakovleva · Zenodo (CERN European Organization for Nuclear Research)
PreprintOpen access |
May 2026 |
0 |
| 25 |
Patterns of practice following treatment recommendation for patients with ductal carcinoma in situ using a 7-Gene predictive biosignature: Analysis of the Australian Predict Registry
Y. Zissiadis, K. rahim, K. Taylor et al. · European Journal of Cancer
|
Mar 2026 |
0 |
| 26 |
Additional file 1 of Development and cross-validation of a novel multi-omic assay to assess locoregional recurrence risk and adjuvant therapy benefit in early-stage hormone receptor positive invasive breast cancer patients
Troy M. Bremer et al. · Figshare
Open access |
18 Feb 2026 |
0 |
| 27 |
Development and cross-validation of a novel multi-omic assay to assess locoregional recurrence risk and adjuvant therapy benefit in early-stage hormone receptor positive invasive breast cancer patients
Troy M. Bremer et al. · Breast Cancer Research
Open access |
18 Feb 2026 |
0 |
| 28 |
The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients with Ductal Carcinoma In Situ
R.A. Rabinovitch, Pat W. Whitworth, Patrick Ivan Borgen et al. · International Journal of Radiation Oncology*Biology*Physics
Open access |
Sep 2025 |
0 |
| 29 |
Novel multi-omic biosignature for identification of early-stage invasive breast cancer patients who do and do not benefit from adjuvant radiation treatment after breast conservation surgery.
Troy M. Bremer, Karuna Mittal, Chirag S. Shah et al. · Journal of Clinical Oncology
|
28 May 2025 |
0 |
| 30 |
TIP25-242: The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients With Ductal Carcinoma In Situ
Rachel A Rabinovitch, Pat W. Whitworth, Patrick Ivan Borgen et al. · Journal of the National Comprehensive Cancer Network
|
28 Mar 2025 |
0 |
| 31 |
ASO Visual Abstract: The Clinical Utility of a 7-Gene Biosignature on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery: An Updated Analysis of the DCISionRT® PREDICT Study
Chirag Shah et al. · Annals of Surgical Oncology
Open access |
15 Jul 2024 |
0 |
| 32 |
Changes in treatment recommendations for patients with ductal carcinoma in situ using a 7-gene predictive biosignature: Analysis of the Australian PREDICT registry
Yvonne Zissiadis, K. Kirkham, Amy C. Driver et al. · European Journal of Cancer
Open access |
Mar 2024 |
0 |
| 33 |
Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women with Low-Risk DCIS after Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Recurrence (IBR) Rates
Frank A. Vicini, Chirag Shah, J. Margenthaler et al. · International Journal of Radiation Oncology*Biology*Physics
Open access |
29 Sep 2023 |
0 |
| 34 |
Impact on Radiation Therapy Recommendation and Treatment Modality for Patients with Ductal Carcinoma In Situ Using the 7Gene Biosignature: Analysis of the PREDICT Study
Chirag Shah, Pat W. Whitworth, Steven C. Shivers et al. · International Journal of Radiation Oncology*Biology*Physics
Open access |
29 Sep 2023 |
0 |
| 35 |
A Biosignature Integrating Immune and Metabolic Signaling Axes to Assess Limited Radiation Therapy Response in Early-Stage Breast Cancer from a Low-Risk Cohort
Troy M. Bremer, Karuna Mittal, F. Wärnberg et al. · International Journal of Radiation Oncology*Biology*Physics
Open access |
29 Sep 2023 |
0 |
| 36 |
In Regard to Woodward and Mitchell
Frank A. Vicini, Troy M. Bremer, Chirag Shah · International Journal of Radiation Oncology*Biology*Physics
|
22 Jun 2023 |
0 |
| 37 |
The PREDICT Registry Australia: A Prospective Registry to Evaluate the Clinical Utility of a Biomarker Assay on Treatment Decisions in Patients with DCIS Following Breast Conserving Surgery
Yvonne Zissiadis, G.B. Mann, D. Speakman et al. · International Journal of Radiation Oncology*Biology*Physics
|
22 Oct 2022 |
0 |
| 38 |
A Novel Biosignature to Assess Residual Risk in Early Stage Invasive Breast Cancer after Standard Breast Conserving Surgery
Troy M. Bremer, Christy Kesslering, Rakesh R. Patel et al. · International Journal of Radiation Oncology*Biology*Physics
Open access |
23 Oct 2020 |
0 |
| 39 |
Age and Grade as a Function of Decision Score in Women Diagnosed with DCIS
Troy M. Bremer, Steven C. Shivers, Christy Kesslering et al. · International Journal of Radiation Oncology*Biology*Physics
|
23 Oct 2020 |
0 |